Literature DB >> 18790331

Focus on breast and ovarian cancer.

A Borini1, E Rebellato.   

Abstract

In reproductive medicine the widespread use of ovarian stimulation has focused interest on the possible relation between induction of ovulation and breast and ovarian cancer. The epidemiological studies published so far are reassuring but not devoid of methodological problems, such as small populations, short follow-ups, and lack of information on confounding factors like oral contraceptive use. In younger patients to preserve fertility before radio- or chemotherapy, the American Society of Clinical Oncology recommended embryo cryopreservation as an established procedure. Moreover, experimental procedure as oocytes cryopreservation, ovarian suppression with GnRH analogues and cortical ovarian tissue freezing probably will be routinely used in the future. A reasonable proposal to protect patients from the risk of estrogen peaks in the case of estrogen receptor positive (ER+) breast cancer, ovarian stimulation with tamoxifen or letrozole could be right. Powered studies are necessary to control the safety and effectiveness of the different fertility preservation options. In this review we evaluated the relation between induction of ovulation and breast and ovarian cancer and then the possible options for fertility preservation in patients with these types of tumors.

Entities:  

Mesh:

Year:  2008        PMID: 18790331     DOI: 10.1016/j.placenta.2008.08.001

Source DB:  PubMed          Journal:  Placenta        ISSN: 0143-4004            Impact factor:   3.481


  2 in total

1.  Combined strategy for fertility preservation in an oncologic patient: vitrification of in vitro matured oocytes and ovarian tissue freezing.

Authors:  Clara González; Marta Devesa; Montserrat Boada; Buenaventura Coroleu; Anna Veiga; Pere N Barri
Journal:  J Assist Reprod Genet       Date:  2011-09-02       Impact factor: 3.412

2.  Oncofertility in Canada: cryopreservation and alternative options for future parenthood.

Authors:  R Ronn; H E G Holzer
Journal:  Curr Oncol       Date:  2014-02       Impact factor: 3.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.